紫杉醇涂层球囊用于血液透析通路的死亡风险与通畅率:系统综述与荟萃分析
该系统综述与荟萃分析纳入16项研究(12项随机对照试验和4项队列研究,共1086例因血液透析通路狭窄或闭塞接受血管内治疗的患者),比较紫杉醇涂层球囊(PCB)与普通球囊(PBA)的通畅率与全因死亡风险。结果显示PCB组6、12、24个月全因死亡率与PBA组相似,而通路原发通畅率显著改善,但回路原发通畅率仅有边缘性改善趋势。
要点
- PCB组6、12、24个月全因死亡率与PBA组无显著差异。
- PCB组通路原发通畅率显著优于PBA组(HR 0.47)。
- PCB在动静脉瘘与中心静脉狭窄中均改善原发通畅率。
核心结论
- PCB血管成形术可显著改善血液透析通路(动静脉瘘及中心静脉狭窄)的原发通畅率。
- 基于短期与中期随访,未见全因死亡风险增加的证据。
- 长期死亡率仍需进一步大型队列研究验证。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和Cochrane数据库。
- 纳入16项研究:12项随机对照试验和4项队列研究,共1086例患者。
- 采用随机效应模型合并效应量,二分类数据用OR,效应数据用合并HR及95%CI。
主要发现
- 6个月全因死亡率:OR 1.06(95%CI 0.38-2.96;P=.907;I2=19.2%)。
- 12个月全因死亡率:OR 1.20(95%CI 0.66-2.16;P=.554;I2=0%)。
- 24个月全因死亡率:OR 1.43(95%CI 0.83-2.45;P=.195;I2=0%)。
- 通路原发通畅率PCB组显著改善:HR 0.47(95%CI 0.33-0.69;P<.001;I2=67.3%)。
- 动静脉瘘亚组HR 0.54(95%CI 0.30-0.98;P=.041),中心静脉狭窄亚组HR 0.39(95%CI 0.22-0.71;P=.002)。
关键数值与推荐
- 病变原发通畅率:6个月OR 0.40(95%CI 0.27-0.59;P<.001);24个月OR 0.28(95%CI 0.11-0.72;P=.009);12个月OR 0.52(95%CI 0.26-1.03;P=.06)。
- 回路原发通畅率:HR 0.63(95%CI 0.40-1.00;P=.052),无统计学显著性。
- 随机对照试验单独分析结果与总体一致,排除队列研究后该获益仍一致。
临床怎么用
- 对血液透析通路狭窄或闭塞的血管内维护治疗,可考虑使用PCB以改善原发通畅率。
- 现有短期至中期证据未提示PCB增加全因死亡风险,可用于临床决策参考。
- 回路原发通畅率获益尚不确切,需结合个体情况评估。
局限性
- 仅基于短期与中期随访评估死亡率,长期安全性数据不足。
- 部分分析异质性较高,如通路原发通畅率I2=67.3%、动静脉瘘亚组I2=76.8%。
- 回路原发通畅率分析仅为边缘性趋势,未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The comparison between paclitaxel-coated balloon (PCB) angioplasty and plain balloon angioplasty (PBA) for hemodialysis (HD) access stenosis or occlusion has not been well investigated. The objectives of this systematic review and meta-analysis were to compare all-cause mortality, HD access primary patency, and circuit primary patency after endovascular maintenance procedures using PCB angioplasty vs PBA. METHODS: MEDLINE, Embase, and Cochrane Databases were systematically searched to identify all the relevant studies on paclitaxel-coated devices for stenosis or thrombosis of HD access. A random effects model was applied to pool the effect measures. Dichotomous data were presented using an odds ratio (OR). Effect data were presented using pooled hazard ratio (HR) with 95% confidence interval (CI). RESULTS: A total of 16 studies were included in this meta-analysis, 12 randomized controlled trials and 4 cohort studies involving 1086 patients who underwent endovascular treatment for HD access stenosis or occlusion. All-cause mortality rates at 6, 12, and 24 months after intervention were similar between the PCB and PBA groups (6 months: OR, 1.06 [95% CI, 0.38-2.96; P = .907; I2 = 19.2%]; 12 months: OR, 1.20 [95% CI, 0.66-2.16; P = .554; I2 = 0%]; 24 months: OR, 1.43 [95% CI, 0.83-2.45; P = .195; I2 = 0%]). There was a significant improvement of primary patency in the PCB group compared with the PBA group (HR, 0.47; 95% CI, 0.33-0.69; P < .001; I2 = 67.3%). This benefit was consistent with the analysis of randomized controlled trials, whereas cohort studies were excluded. Further subgroup analysis of target lesions demonstrated that primary patency was significantly higher in the PCB group than in the PBA group, not only for arteriovenous fistula (HR, 0.54; 95% CI, 0.30-0.98; P = .041; I2 = 76.8%) but also for central venous stenosis (HR, 0.39; 95% CI, 0.22-0.71; P = .002; I2 = 0%). The PCB group was associated with higher 6-month (OR, 0.40; 95% CI, 0.27-0.59; P < .001) and 24-month lesion primary patency (OR, 0.28; 95% CI, 0.11-0.72; P = .009) than PBA and was marginally associated with 12-month lesion primary patency (OR, 0.52; 95% CI, 0.26-1.03; P = .06). Circuit primary patency analysis showed a marginal trend toward better outcome in the PCB group (HR, 0.63; 95% CI, 0.40-1.00) but no statistical significance (P = .052). CONCLUSIONS: This systematic review and meta-analysis demonstrated that PCB angioplasty is associated with significantly improved primary patency of arteriovenous fistula and central venous stenosis for HD access maintenance, with no evidence of increasing all-cause mortality based on short-term and midterm follow-up. Further large cohort study is needed to investigate long-term mortality.
引用
- Chen X, Liu Y, Wang J, et al. A systematic review and meta-analysis of the risk of death and patency after application of paclitaxel-coated balloons in the hemodialysis access. J Vasc Surg. 2020. PMID: 32540324. doi:10.1016/j.jvs.2020.04.525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。